Format

Send to

Choose Destination
Vaccine. 2015 May 5;33(19):2261-2266. doi: 10.1016/j.vaccine.2015.03.029. Epub 2015 Mar 25.

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.

Author information

1
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
2
Vaccine and Gene Therapy Institute, Oregon Health & Sciences University, Portland, Oregon, USA.
3
Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
4
Centre for Biostatistics, Bioinformatics and Biomarkers, University of Plymouth, Devon, UK.
5
School of Medicine, University of California, Riverside, California, USA.
6
Helmholtz Centre for Infection Research, Braunschweig, Germany.
7
School of Biomedical and Healthcare Sciences, University of Plymouth, Devon, UK. Electronic address: michael.jarvis@plymouth.ac.uk.

Abstract

Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

KEYWORDS:

Cytomegalovirus; Disseminating; Durable; Ebola; Ebolavirus; Great apes; Mouse; Protection; Vaccine

PMID:
25820063
PMCID:
PMC4402448
DOI:
10.1016/j.vaccine.2015.03.029
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center